-

Evommune to Present at Upcoming Investor Conferences

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced presentations by management at the following upcoming investor conferences:

  • Stifel Healthcare Conference 2026 in New York: Fireside Chat on Wednesday, November 11, 2026, at 4:40 p.m. ET.
  • 2026 Jefferies Global Healthcare Conference in London: Presentation on Wednesday, November 18, 2026, at 6:00 a.m. ET (11:00 a.m. GMT)
  • 9th Annual Evercore Healthcare Conference in Coral Gables, FL: Fireside Chat on Wednesday, December 2, 2026, at 10:25 a.m. ET.

All webcasted presentations will be available on the News & Events section of the Company’s website at www.evommune.com. Archived replays will be available for 30 days.

About Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that result from the limitations of existing therapies. For more information, please visit www.evommune.com and follow us on LinkedIn.

Contacts

Media and Investors:
Megan Humphreys
megan.humphreys@evommune.com

Industry:

Evommune, Inc.

NYSE:EVMN
Release Versions
English

Contacts

Media and Investors:
Megan Humphreys
megan.humphreys@evommune.com

More News From Evommune, Inc.

Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President and Chief Executive Officer Luis Peña and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular gl...

Evommune Announces $30 Million Private Placement

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $6.0...

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

PALO ALTO, Calif. & NEW YORK & CHENGDU, China--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302) today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed mol...
Back to Newsroom